|Bid||0.00 x 800|
|Ask||0.00 x 800|
|Day's Range||28.71 - 29.85|
|52 Week Range||14.81 - 37.95|
|Beta (3Y Monthly)||2.48|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 5, 2019 - Nov 11, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||42.00|
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
SOUTH SAN FRANCISCO, Calif., Aug. 13, 2019 /PRNewswire/ -- Portola Pharmaceuticals, Inc. (PTLA) today announced the pricing of its underwritten public offering of 8,035,715 shares of its common stock at a price to the public of $28.00 per share. In addition, the underwriters of the offering have been granted a 30-day option to purchase up to an additional 1,205,357 shares from Portola at the public offering price. Goldman Sachs & Co. LLC, Citigroup, Cowen, and William Blair are acting as joint book-running managers.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Aug. 12) GENMAB A/S/S ADR (NASDAQ: GMAB ) (IPOed July 1) Down ...
SOUTH SAN FRANCISCO, Calif., Aug. 12, 2019 /PRNewswire/ -- Portola Pharmaceuticals, Inc.® (PTLA) today announced plans to offer, subject to market and other conditions, $200 million of its common stock in an underwritten public offering. The company expects to grant the underwriters a 30-day option to purchase up to an additional $30 million of its common stock in connection with the offering. All of the shares of common stock in the offering will be sold by Portola Pharmaceuticals.
Portola Pharmaceuticals (PTLA) delivered earnings and revenue surprises of 12.38% and 17.04%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
- Second Quarter Revenues of $28.4 Million ; Andexxa® Net Product Revenues Grow to $27.1 Million - - Launched Ondexxya® (andexanet alfa) with First Orders in Europe - - U.S. Centers for Medicare and Medicaid ...
Endo (ENDP) beats on both sales and earnings in the second quarter of 2019. However, both metrics decline year over year due to weak generic business.
SOUTH SAN FRANCISCO, Calif., Aug. 6, 2019 /PRNewswire/ -- Portola Pharmaceuticals, Inc.® (PTLA) today announced the Company's first sales of Ondexxya® (andexanet alfa) in Europe. Portola is executing a phased launch of Ondexxya in Europe, with an initial focus on Germany, Austria, the United Kingdom, the Netherlands, Sweden, Denmark and Finland, where Factor Xa inhibitor use, and related bleeds, are among the highest in Europe.
SOUTH SAN FRANCISCO, Calif., Aug. 5, 2019 /PRNewswire/ -- Portola Pharmaceuticals, Inc.® (PTLA) today announced that the U.S. Centers for Medicare and Medicaid Services (CMS) has increased the maximum reimbursement amount for the New Technology Add-on Payment (NTAP) granted in October 2018 to Andexxa® [coagulation factor Xa (recombinant), inactivated-zhzo] from 50 percent to 65 percent. The final rule concerning the Hospital Inpatient Prospective Payment System and CMS Fiscal Year 2020 was pre-published online Friday, August 2, 2019 (pages 420-422) (https://s3.amazonaws.com/public-inspection.federalregister.gov/2019-16762.pdf), and will be formally published in the Federal Register on Friday, August 16, 2019. "Today's CMS decision supports the breakthrough innovation of Andexxa and the clinical value of rapidly reversing the anticoagulant effects of the Factor Xa inhibitors rivaroxaban and apixaban in the event of life-threatening or uncontrolled bleeding," said Scott Garland, Portola's president and chief executive officer.
Portola Pharmaceuticals (PTLA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
SOUTH SAN FRANCISCO, Calif. , July 17, 2019 /PRNewswire/ -- Portola Pharmaceuticals, Inc. ® (NASDAQ: PTLA) today announced that it will host a webcast and conference call to discuss the Company's financial ...
SOUTH SAN FRANCISCO, Calif., July 8, 2019 /PRNewswire/ -- Portola Pharmaceuticals, Inc.® (PTLA) today announced new in vitro data establishing the relationship between concentrations of the direct oral anticoagulants (DOACs) apixaban and rivaroxaban and the ability of four-factor prothrombin complex concentrate (4F-PCC) to correct inhibition of thrombin generation, compared with warfarin anticoagulation reversal by 4F-PCC. Results showed that, while effective in reversing inhibition of thrombin generation in plasma from patients treated with warfarin, 4F-PCCs did not appear to have an effect on the inhibition of thrombin generation by apixaban or rivaroxaban unless the Factor Xa inhibitor concentration was less than 75 ng/mL.
SOUTH SAN FRANCISCO, Calif., June 19, 2019 /PRNewswire/ -- Portola Pharmaceuticals, Inc.® (PTLA) today announced new interim results from the Company's ongoing Phase 2a study of cerdulatinib, an investigational, oral SYK/JAK inhibitor, in patients with relapsed/refractory follicular lymphoma (FL) receiving cerdulatinib alone or in combination with rituximab. Data were presented this month in a poster session at the 24th Congress of the European Hematology Association (EHA) in Amsterdam (June 13-16) and during an oral session today at the 15th International Conference on Malignant Lymphoma (ICML) in Lugano, Switzerland (June 18-22).
Portola Pharmaceuticals Inc NASDAQ/NGS:PTLAView full report here! Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is high * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | NegativeShort interest is extremely high for PTLA with more than 20% of shares on loan. This means that investors who seek to profit from falling equity prices are currently targeting PTLA. Money flowETF/Index ownership | PositiveETF activity is positive. Over the last month, ETFs holding PTLA are favorable, with net inflows of $2.34 billion. Additionally, the rate of inflows is increasing. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to email@example.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
SOUTH SAN FRANCISCO, Calif., May 28, 2019 -- Portola Pharmaceuticals, Inc.® (Nasdaq: PTLA) today announced that Scott Garland, Portola’s president and chief executive officer,.
Amicus or Portola: Which Is the Best Bet in May?(Continued from Prior Part)European market launchOn April 26, Portola Pharmaceuticals (PTLA) issued a press release announcing conditional marketing authorization granted by the European Commission to
Amicus or Portola: Which Is the Best Bet in May?(Continued from Prior Part)Reimbursement and accessIn its first quarter earnings conference call, Portola Pharmaceuticals (PTLA) highlighted the stocking of Andexxa by 300 hospitals in the US with a